Cleveland Clinic Riding the Wave:
Clinical
Management of Myeloid Malignancies
in an
Era of
Novel Therapies
One, If by Land, Two If by Sea: Combination Therapies for AML
Release Date: January 17, 2019
Expiration Date: January 17, 2021
Estimated Time of Completion: 15 minutes
Description
One, If by Land, Two If by Sea: Combination Therapies for AML webcast, part of the Riding the Wave: Clinical Management of Myeloid Malignancies in an Era of Novel Therapies online series, will provide an in-depth overview of the efficacy and side effects of combination therapies for acute myeloid leukemia.
Disclosures
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty has indicated that he has a relationship, which in the context of his presentation(s), could be perceived as a potential conflict of interest:
Steven Gore, MD | ||
Celgene Corporation | Consulting | |
The following faculty has indicated he has no relationship which, in the context of his presentation(s), could be perceived as a potential conflict of interest:
Matt Kalaycio, MD
The Cleveland Clinic Foundation Center for Continuing Education
acknowledges educational grants for partial support of the Internet Enduring activity from:
Alexion Pharmaceuticals, Inc.
Apellis Pharmaceuticals
Celgene Corporation
Geron Corporation
Millennium Pharmaceuticals, Inc.
Onconova Therapeutics, Inc.
RA Pharmaceuticals, Inc.
This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education,
Cleveland Clinic’s Taussig Cancer Institute and Aplastic Anemia & MDS International Foundation.